Drug Profile
Ropanicant - Suven Life Sciences
Alternative Names: SUVN-911Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Suven Life Sciences
- Class Antidepressants; Aza compounds; Cyclohexanes; Cyclopropanes; Heterocyclic bicyclo compounds; Pyridines; Small molecules
- Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 20 Jan 2024 Phase-II clinical trials in Major depressive disorder in USA (PO) (NCT06126497)
- 14 Nov 2023 Suven Life Sciences plans a phase II trial for Major depressive disorder in January 2024 (PO, Tablet) (NCT06126497)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA (PO, Tablet)